多学科团队合作模式下1例多发性骨髓瘤患者个体化给药方案调整的病例分析
天津医科大学总医院, 药剂科, 天津 300052
| 摘 要： | 目的：介绍多学科团队合作模式下多发性骨髓瘤的个体化给药方案的制定与调整，逐步开展药师在血液肿瘤中的药学工作，强化血液肿瘤多学科团队合作。方法 ：药师通过1例多发性骨髓瘤患者病例分析，学习血液肿瘤个体化给药临床理论依据，积累临床经验。结果：药师结合药学理论知识，通过个体化给药的病例分析，理论联系实际为开展多学科团队合作打下基础。结论：药师参与血液肿瘤多学科合作团队能够充分发挥精通药学知识优势，与临床医生合作，协助制定个性化治疗方案，提高药物治疗水平，为患者提供最佳药物治疗方案。 |
| 关 键 词： | 多学科团队; 多发性骨髓瘤; 个体化给药 |
| DOI： | 10.57237/j.life.2024.04.001 |
View:
Downloads:
收稿日期: 2024-10-14
接受日期: 2024-11-23
在线出版日期: 2024-12-05
Case Analysis of Administration Adjustment of Individualized Treatment of a Patient with Multiple Myeloma Under Multidisciplinary Team Mode
Department of Pharmacy, General Hospital of Tianjin Medical University, Tianjin 300052, China
| Abstract: | Objective: To explore the formulation of individualized drug administration plan for multiple myeloma under multidisciplinary team mode, carry out the pharmaceutical work in hematological tumors gradually, strengthen multidisciplinary team cooperation. Methods: Pharmacists learned the theoretical basis of individual MM administration and accumulated clinical experience through case analysis of 1 MM patient. Results: Pharmacists combined with the theoretical knowledge of pharmacy, lay a foundation for the development of clinical pharmaceutical care of hematological tumor, through the case analysis of MM patients with individual drug administration. Conclusion: Pharmacists participate in hematologic tumor multidisciplinary team that can improve the level of drug treatment, and provide the best drug treatment plans for patients through giving full play to their advantages in pharmaceutical knowledge and cooperating with clinicians. |
| Keywords: | Multidisciplinary Team; Multiple Myeloma; Individualized Drug Administration |
参考文献
| [1] | 金炜, 管俊, 陈家楠, 等. 多发性骨髓瘤骨病发病机制及治疗的研究进展 [J]. 中华临床医师杂志 (电子版) 2018, 12(11): 630-634. |
| [2] | 庄兰. 不同剂量硼替佐米联合阿霉素及地塞米松治疗多发性骨髓瘤临床疗效的比较研究 [J]. 临床合理用药志, 2019, 12(24): 63-64. |
| [3] | Soave C L, Guerin T, Liu J, et al. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing [J]. Cancer Metastasis Rev, 2017, 36(4): 717-736. |
| [4] | Voorhees PM, Gasparetto C, Moore DT, et al. Final results of a phase 1 study of vorinostat, pegylated liposomal doxorubicin, and bortezomib in relapsed or refractory multiple myeloma [J]. Clin Lymphoma Myeloma Leuk, 2017, 17(7): 424-432. |
| [5] | Orlowski RZ, Nagler A, Sonneveld P, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with re lapsed or refractory multiple myeloma [J]. Cancer, 2016, 122(13): 2050-2056. |
| [6] | Chinese Physicians Association Blood Physician Branch Multiple Myeloma Professional Committee. Diagnosisand treatment of multiple myeloma peripheral neuropathy [J]. Chin J Inter Med (中华内科杂志), 2015, 54(9): 821-824. |
| [7] | Ling P, Ye X, Yun Z, etal. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib [J]. Soppor Care Cancer, 2015, 23(9): 2813-2824. |
| [8] | Qin H, Wang Y, Ding S, etal. Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma [J]. J Sichuan Univ (Med Sci Edi) (四川大学学报医学版), 2014, 45(3): 529-532. |
| [9] | 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南 [J]. 中华血液学杂志, 2016, 37(5): 353-359. |
| [10] | 刘申香, 汪竹, 袁昕, 等. 肿瘤化疗致Ⅳ度骨髓抑制临床观察与分析 [J]. 中国老年保健医学, 2015, 13(2): 95-97. |
| [11] | 刘倩欣, 向倩, 张卓, 等. 乳腺癌患者化疗药物不良反应情况及影响因素分析 [J]. 中国临床药理学杂志, 2018, 34(4): 475-478. |
| [12] | LARIBI K, BOLLE D, ALANI M, et al. Impact of the relative dose intensity on survival of patients with high -risk myelodysplastic syndromes treated with Azacitidine [J]. Cancer Med, 2019, 8(5): 2188-2195. |
| [13] | KEATING M, DASANU CA. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function [J]. BMJ CaseＲep, 2016: bcr2016217000. |
| [14] | GUPTAN, HANLEY MJ, XIA C, et al. Clinical pharmacology of ixazomib: The first oral proteasome inhibitor [J]. Clin Pharmacokinet, 2019, 58(4): 431-449. |
| [15] | KUPPEＲMAN E, LEE EC, CAO Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer [J]. Cancer Res, 2010, 70(5): 1970-1980. |
| [16] | CLEMENS J, WELTI L, SCHAFER J, et al. Bortezomib carfilzomib and ixazomib do not mediate relevant transporter based drug -drug interactions [J]. Oncol Lett, 2017, 14(3): 3185-3192. |
